Michiel de Haan

Michiel de Haan has been active in life sciences since 1987 when he spun-out Atlas Venture from the ING bank. Under his leadership Atlas developed into a European-American venture capital firm with offices in Amsterdam, Munich, Boston and London and invested in over 300 venture backed companies in Information Technology and Life Sciences. Michiel has been active on numerous boards of Life Science companies such as Crucell and Morphosys.

Michiel is past chairman of the European Venture Capital Association (EVCA) and co-founder of the European Venture Philanthropy Association (EVPA). In 1974 Michiel received an MBA from Erasmus University in Rotterdam. From 1974 until 1980 he worked at NMB (now ING). He started NMB-Participatie, which he later bought to create Atlas Venture. Currently he is General Partner of Aescap Venture that he co-founded in 2005 and is a fund advisor to Aescap 2.0, besides being actively involved in Venture Philanthropy.

Michiel is board member of the Aqre Group that has invested in two companies in Madagascar where they’re cooperating with 20,000 farmers to plant Artemisia Annua, the raw material for artemisinin, which is the only working medicine and first line treatment to cure malaria.

The Aqre Group also has a production facility for quinine of which the raw material is the bark of the Cinchona tree. Quinine is delivered to the beverage industry and the flavour- and fragrances industry.